StockData
Aytu BioPharma, Inc logo

Aytu BioPharma, Inc (AYTU) stock

AYTUNasdaqPharmaceutical PreparationsFiscal year ends June 30
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 22, 2026Score 9/3079% below fair value
$1.78−0.01 (-0.56%)

Close on Nov 13, 2026Market cap $19.34MP/E –Yield –

Aytu BioPharma operating margin

Operating margin is operating income as a percentage of revenue.

Aytu BioPharma's operating margin for the twelve months ending Jun 30, 2026 was -14.4%. For fiscal 2026 it was -14.4%, against -11.8% the year before. The highest annual figure on record is -2.4% in fiscal 2024.

Annual operating margin

PeriodPeriod endValueChange (pts)
FY2026Jun 30, 2026-14.4%−2.7
FY2025Jun 30, 2025-11.8%−9.4
FY2024Jun 30, 2024-2.4%+13.4
FY2023Jun 30, 2023-15.9%+97.8
FY2022Jun 30, 2022-113.7%−24.0
FY2021Jun 30, 2021-89.7%−13.2
FY2020Jun 30, 2020-76.5%+153.7
FY2019Jun 30, 2019-230.1%+308.1
FY2018Jun 30, 2018-538.2%+86.5
FY2017Jun 30, 2017-624.7%+222.3
FY2016Jun 30, 2016-847.0%+2068.5
FY2015Jun 30, 2015-2915.5%+79.6
FY2013Aug 31, 2013-2995.1%+225.3
FY2012Aug 31, 2012-3220.3%–

Quarterly operating margin

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange (pts)
Q4 FY2026CQ2 2026Jun 30, 2026-4.8%+45.5
Q3 FY2026CQ1 2026Mar 31, 2026-32.7%−45.9
Q2 FY2026CQ4 2025Dec 31, 2025-13.0%−2.5
Q1 FY2026CQ3 2025Sep 30, 2025-10.8%−5.2
Q4 FY2025CQ2 2025Jun 30, 2025-50.4%−34.8
Q3 FY2025CQ1 2025Mar 31, 202513.1%+24.5
Q2 FY2025CQ4 2024Dec 31, 2024-10.4%−27.2
Q1 FY2025CQ3 2024Sep 30, 2024-5.6%−0.7
Q4 FY2024CQ2 2024Jun 30, 2024-15.6%−16.1
Q3 FY2024CQ1 2024Mar 31, 2024-11.4%+26.3
Q2 FY2024CQ4 2023Dec 31, 202316.8%+42.9
Q1 FY2024CQ3 2023Sep 30, 2023-4.9%+1.7
Q4 FY2023CQ2 2023Jun 30, 20230.5%+62.3
Q3 FY2023CQ1 2023Mar 31, 2023-37.6%+183.1
Q2 FY2023CQ4 2022Dec 31, 2022-26.1%+22.7
Q1 FY2023CQ3 2022Sep 30, 2022-6.5%+120.0
Q4 FY2022CQ2 2022Jun 30, 2022-61.7%+40.8
Q3 FY2022CQ1 2022Mar 31, 2022-220.8%−30.4
Q2 FY2022CQ4 2021Dec 31, 2021-48.8%−12.0
Q1 FY2022CQ3 2021Sep 30, 2021-126.5%−100.2
Q4 FY2021CQ2 2021Jun 30, 2021-102.5%−57.9
Q3 FY2021CQ1 2021Mar 31, 2021-190.4%−131.6
Q2 FY2021CQ4 2020Dec 31, 2020-36.8%+119.6
Q1 FY2021CQ3 2020Sep 30, 2020-26.3%+302.6
Q4 FY2020CQ2 2020Jun 30, 2020-44.6%+222.3
Q3 FY2020CQ1 2020Mar 31, 2020-58.8%+122.0
Q2 FY2020CQ4 2019Dec 31, 2019-156.4%+97.1
Q1 FY2020CQ3 2019Sep 30, 2019-328.9%−90.2
Q4 FY2019CQ2 2019Jun 30, 2019-266.9%+146.7
Q3 FY2019CQ1 2019Mar 31, 2019-180.8%+1057.9
Q2 FY2019CQ4 2018Dec 31, 2018-253.5%+126.4
Q1 FY2019CQ3 2018Sep 30, 2018-238.7%+166.0
Q4 FY2018CQ2 2018Jun 30, 2018-413.6%+196.5
Q3 FY2018CQ1 2018Mar 31, 2018-1238.7%−694.8
Q2 FY2018CQ4 2017Dec 31, 2017-380.0%+148.7
Q1 FY2018CQ3 2017Sep 30, 2017-404.7%+450.1
Q4 FY2017CQ2 2017Jun 30, 2017-610.2%–
Q3 FY2017CQ1 2017Mar 31, 2017-543.9%–
Q2 FY2017CQ4 2016Dec 31, 2016-528.7%–
Q1 FY2017CQ3 2016Sep 30, 2016-854.8%–

More Aytu BioPharma figures

See a number that looks wrong?